EP
PMVP icon

Eversept Partners’s PMV Pharmaceuticals PMVP Stock Holding History

Eversept Partners’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53M Sell
1,890,904
-457,456
-19% -$587K 0.13% 87
2026
Q1 		$2.91M Buy
+2,348,360
New +$2.99M 0.15% 78

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners's PMVP Position: Q2 2026 in Review

Eversept Partners reduced its PMV Pharmaceuticals (PMVP) stake by 19% in Q2 2026, selling an estimated $587K and leaving 1,890,904 shares worth $2.53M. The position accounts for 0.13% of the portfolio, ranked #87.

Eversept Partners first reported a position in PMVP in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.91M in Q1 2026. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

  • Eversept Partners held 1,890,904 shares of PMV Pharmaceuticals worth $2.53M as of Q2 2026.
  • Eversept Partners sold 457,456 PMV Pharmaceuticals shares in Q2 2026, an estimated $587K.
  • PMV Pharmaceuticals made up 0.13% of Eversept Partners's portfolio in Q2 2026, its #87 holding.
  • Eversept Partners first reported a position in PMV Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Eversept Partners's PMV Pharmaceuticals position peaked at $2.91M in Q1 2026.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.